Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
casdozokitug + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Coherus BioSciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of casdozokitug (a first-in-class IL-27-targeting antibody) and pembrolizumab (a PD-1 inhibitor). This combination aims to enhance anti-tumor immune responses by simultaneously blocking IL-27 signaling and the PD-1 pathway, potentially overcoming resistance to PD-1 inhibition alone.
- Brand names
- Keytruda
- Other names
- casdozo + pembrolizumab
02
Targets
IL-27 (Interleukin-27)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on casdozokitug + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on casdozokitug + pembrolizumab.